When the platform sells, physicians often focus on the sale price. But their actual outcome may depend less on that headline number than on questions buried in the documents they signed years earlier when they rolled equity into a private-equity backed platform: where their equity sits in the waterfall, whether they can be forced to roll again, what happens if they retire, and whether the new buyer’s equity is materially worse than what they held before. Physicians experience the first sale as a negotiation. They experience the second sale as a document they have already signed.
This article addresses both scenarios—whether you are approaching an exit and need to understand what your existing agreements provide or evaluating a first-time rollover and want to know what an exit will look like before you commit. For physicians earlier in this process, see our guide to preparing your medical practice for a private equity transaction.
Why physicians are often surprised at exit
It happens consistently: physicians focus on enterprise value rather than distribution priority, because enterprise value is the number everyone talks about. They assume “rollover” means continuity of the same investment when it often means a different security on a different cap table with different terms. Retirement and leaver provisions get underestimated until they apply personally. The possibility of new restrictive covenants or a mandatory re-investment goes unexamined.
The exit paths for physician rollover equity at a platform-level liquidity event will follow one of three paths. In many transactions, a physician’s consideration will be a blend of more than one.
1. Full cash-out. The physician’s equity is redeemed entirely for cash at closing. This is the cleanest outcome, but the cash the physician actually receives depends on where their equity sits in the distribution waterfall—after debt, preferred returns, sponsor economics, and transaction expenses.
2. Partial cash-out, partial rollover. The physician receives some cash at closing and rolls the remainder into the new buyer’s acquisition vehicle. The rollover percentage may be set by the existing operating agreement or imposed by the incoming buyer as a closing condition. In either case, the physician’s ability to influence the split is often limited.
3. Rollover or exchange into new buyer equity. “Rollover” often suggests continuity. In practice, it may mean exchanging into a materially different instrument—different class, different priority, different vesting, different leaver treatment, different waterfall position. Physicians should approach every re-roll as a new investment decision, not a continuation of an existing one. This is especially important where physicians joined the platform at different times: those who rolled at the original acquisition and those added through later tuck-in deals may hold different equity classes, different cost bases, and different vesting schedules—and the new structure may not preserve those distinctions.
Why the sales price doesn’t determine your payout
The platform sold well—so why is the physician’s payout lower than expected? Because the distribution waterfall, not the enterprise value, determines what physicians actually receive.
In a typical sponsor-controlled structure, exit proceeds flow in this order: repayment of outstanding platform debt and transaction expenses; return of the sponsor’s preferred capital and accrued preferred return; satisfaction of any liquidation preferences held by senior equity classes; and finally, distribution to common equity holders, which is where most physician rollover sits. The waterfall may also reflect leverage added during the hold period, including debt-funded sponsor dividends that increase the platform's debt stack and reduce the equity cushion available to common holders at exit.
Physicians should pay close attention to whether the sponsor’s preferred equity is participating or non-participating. Participating preferred entitles the sponsor to its liquidation preference and a pro rata share of the remaining proceeds alongside common holders, thereby compressing the common equity’s share of upside. In a leveraged platform, the distinction between participating and non-participating preferred can be the difference between a substantial or a marginal return for physicians holding common equity.
Sponsor-carried interest, monitoring fees, transaction advisory fees, and other forms of leakage further reduce the pool before common holders participate—five terms to review before rolling into a second platform. For many physicians, the exit will not be a full cash-out. They will be asked—or required—to roll some or all of their equity into the next platform. When that happens, the following terms will largely determine the physician’s economic outcome for the next five to seven years.
1. Where the re-rolled equity sits in the new capital stack
The new buyer’s capital structure is not a continuation of the old one. Physicians rolling into a new platform should understand the incoming sponsor’s preferred return, the new debt stack, the fee structure, and where the physician’s re-rolled equity sits in the distribution priority. A physician who held common equity behind one layer of preferred may find the new structure adds additional layers of senior capital—or imposes a participating preferred security that did not exist before.
2. Whether the new equity is fully earned or has to vest again
Second-roll equity is frequently treated partly as retention equity. That means it may be subject to a new vesting schedule that starts from zero, regardless of how long the physician has been with the platform. Vesting that resets on a change of control, rather than accelerating, can convert what the physician understood as fully earned equity into a multi-year earn-back under a new owner.
3. What happens if you retire, resign, or are terminated
Leaver provisions govern the economic treatment of a physician’s equity upon departure, and outcomes vary significantly across deals. The typical framework distinguishes “good leavers” from “bad leavers,” but the actual spectrum is broader—and more consequential —than these labels suggest.
A “good leaver” is typically defined to include retirement at a specified age, death, disability, or termination without cause. It will generally retain vested equity and receive repurchase consideration at fair market value (FMV). But physicians should not assume good-leaver status guarantees full FMV recovery. Some agreements apply minority or marketability discounts, valuation caps, or use a formula-based price that may fall below true FMV. In more sponsor-favorable structures, even a good leaver may receive only a percentage of FMV or a blended rate between FMV and cost basis.
A “bad leaver” can include voluntary resignation, termination for cause, breach of restrictive covenants, and faces the most punitive outcomes: forfeiture of all unvested equity and repurchase of vested equity at cost, meaning the physician receives only the original rollover amount with no share of appreciation.
For the physician within ten years of retirement at the time of a second rollover, the leaver framework can be the most likely exit path out of the investment. Physicians should confirm whether retirement qualifies as a good-leaver event, at what age, with what notice requirements, and whether that classification requires board consent or is automatic. Ambiguity in retirement treatment is one of the most common sources of physician-sponsor disputes in healthcare platform transactions.
4. Who can buy back your equity, and when you actually get paid
Most physician equity agreements grant the company or sponsor a repurchase right upon departure. The economics depend on leaver classification, but even a favorable classification may not mean prompt liquidity.
For a good leaver, repurchase is typically at FMV—but FMV repurchases may be paid not in cash at departure, but through a promissory note payable only upon a future exit event. This means a retiring physician’s equity value may remain illiquid and at risk until the platform is ultimately sold—potentially years after the physician has stopped practicing. Some of these notes are subordinated to platform debt, carry no stated interest rate, and have no fixed maturity date.
For a bad leaver, repurchase is commonly at cost—the original rollover amount, no appreciation, regardless of platform performance.
5. Whether you can be forced to sell, reinvest, or sign new restrictions
Drag-along provisions give the sponsor the contractual right to compel all equity holders to participate in a sale. Physicians will not have the ability to opt out.
The key protection is “same form, same terms”—a requirement that dragged holders receive the same type and economics of consideration as the sponsor. But physicians should confirm this extends to all components—cash, equity, notes, earnouts, escrows, and holdbacks—not just the headline price.
- New non-competes at closing. Exit transactions almost always require physicians to enter into new restrictive covenants with the buyer as a condition of closing. Physicians have limited leverage to resist but should negotiate scope, duration, and geographic reach—particularly in states where enforceability standards are changing. Whether the new noncompete is a condition of receiving deal consideration or merely a buyer request can materially affect the physician's negotiating position, and the distinction is not always made clear during the sale process.
- Restrictive covenants: The triple non-compete problem. Physicians participating in a platform exit are often subject to restrictive covenants in three separate agreements simultaneously: the purchase agreement, the operating agreement governing rollover equity, and the employment agreement with the practice. Each serves a different commercial purpose, is typically negotiated at a different stage of the transaction, and may be triggered by different events: the purchase agreement non-compete running from closing, the operating agreement non-compete triggered by departure from the platform, and the employment agreement non-compete triggered by termination of employment. Because these provisions arise in different documents, they frequently have different geographic scopes, durations, and carve-outs, and a physician leaving the platform after an exit may face overlapping restrictions that run concurrently or are triggered sequentially. Retirement presents a particular risk. A physician who departs in good standing under the employment agreement may nonetheless trigger a separate restriction under the operating agreement if retirement is not expressly carved out.
- Minimum rollover and reinvestment requirements. These may be imposed by the original operating agreement or by the incoming buyer. Physicians approaching retirement should evaluate whether a forced multi-year illiquid hold aligns with their liquidity needs.
- Indemnity exposure at exit. At exit, physicians as selling equity holders will be subject to indemnification obligations for breaches of representations and warranties. In a roll-up platform with dozens or hundreds of physician holders, the allocation of this exposure matters. The critical questions are whether liability is several-only or joint and several; who controls settlement of claims; whether the holder representative can settle from the escrow without individual consent; and whether the buyer’s representation and warranty insurance covers healthcare regulatory representations or carves them out—leaving the physicians’ escrow as the primary recovery path for the highest-risk claims.
Exit friction: Why signing is not closing
Physician-platform transactions are increasingly subject to state healthcare transaction review laws and notice requirements that can extend the period between signing and closing. These include physician-practice-specific notice rules and broader, mini-HSR style frameworks that now exist in a growing number of jurisdictions.
A multi-month closing delay can change whether a physician’s vesting is complete at closing, whether a retirement qualifies as a good-leaver event tied to the closing date rather than the signing date, and whether rollover and escrow timing align with the physician’s personal financial planning.
What physicians should do next
The second sale is not simply a payday. It is a contractual reset.
For many physicians, the real question at exit is not whether the platform sold well. It is whether the documents convert that sale into cash, a second illiquid hold, or new equity with materially different economics.
The time to understand these provisions is before the initial rollover, not at the exit closing table. The Nixon Peabody Healthcare Transaction team regularly advises physician groups navigating these structures. If you have a question about an existing rollover agreement or an upcoming platform sale, reach out to your Nixon Peabody attorney or the authors of this article to discuss.
Five questions every physician with rollover equity should ask before the platform sells:
1. What sits ahead of my equity class in the exit waterfall? Debt, preferred returns, sponsor economics, and fee leakage all reduce proceeds before your equity participates.
2. Can I be required to roll again—and how much? The operating agreement, or the incoming buyer, imposes a mandatory rollover percentage, with limited or no age- or service-based carve-outs.
3. What happens to my equity if I retire before the next exit? Whether retirement triggers good-leaver treatment, the applicable repurchase price, and whether payment is in cash or a promissory note payable only on exit can vary significantly by agreement.>
4. Can my equity be repurchased, at what price, and when is it actually paid? FMV repurchase with prompt payment and FMV repurchase via a subordinated note with no fixed maturity are materially different outcomes.
5. Will I have to sign new restrictive covenants to participate in the sale? The scope, duration, and geography of exit-related non-competes may differ significantly from those in existing agreements and may be a condition of receiving deal consideration.